Advances in the Pathogenesis and Treatment of Resistant Hypertension

被引：7

作者：

Dybiec, Jill ^{[1
]}

Krzeminska, Julia ^{[1
]}

Radzioch, Ewa ^{[1
]}

Szlagor, Magdalena ^{[1
]}

Wronka, Magdalena ^{[1
]}

Mlynarska, Ewelina ^{[1
]}

Rysz, Jacek ^{[2
]}

Franczyk, Beata ^{[1
]}

机构：

[1] Med Univ Lodz, Dept Nephrocardiol, Ul Zeromskiego 113, PL-90549 Lodz, Poland

[2] Med Univ Lodz, Dept Nephrol Hypertens & Family Med, Ul Zeromskiego 113, PL-90549 Lodz, Poland

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2023年 / 24卷 / 16期

关键词：

hypertension; blood pressure measurement; secondary hypertension; renal denervation; antihypertensive drugs; resistant hypertension; BAROREFLEX ACTIVATION THERAPY; LOWERS BLOOD-PRESSURE; OBSTRUCTIVE SLEEP-APNEA; ROX CONTROL HTN; UNCONTROLLED HYPERTENSION; ARTERIOVENOUS ANASTOMOSIS; RENAL DENERVATION; PREVALENCE; DIAGNOSIS; APPARENT;

D O I：

10.3390/ijms241612911

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Hypertension is a prevalent chronic disease associated with an increased risk of cardio-vascular (CV) premature death, and its severe form manifests as resistant hypertension (RH). The accurate prevalence of resistant hypertension is difficult to determine due to the discrepancy in data from various populations, but according to recent publications, it ranges from 6% to 18% in hypertensive patients. However, a comprehensive understanding of the pathogenesis and treatment of RH is essential. This review emphasizes the importance of identifying the causes of treatment resistance in antihypertensive therapy and highlights the utilization of appropriate diagnostic meth-ods. We discussed innovative therapies such as autonomic neuromodulation techniques like renal denervation (RDN) and carotid baroreceptor stimulation, along with invasive interventions such as arteriovenous anastomosis as potential approaches to support patients with inadequate medical treatment and enhance outcomes in RH.

引用

页数：16

共 67 条

[21] Blood pressure and the new ACC/AHA hypertension guidelines [J].

Flack, John M. ;

Adekola, Bemi .

TRENDS IN CARDIOVASCULAR MEDICINE, 2020, 30 (03) :160-164

[22] Clinical characteristics of patients with resistant hypertension: the RESIST-POL study [J].

Florczak, E. ;

Prejbisz, A. ;

Szwench-Pietrasz, E. ;

Sliwinski, P. ;

Bielen, P. ;

Klisiewicz, A. ;

Michalowska, I. ;

Warchol, E. ;

Januszewicz, M. ;

Kala, M. ;

Witkowski, A. ;

Wiecek, A. ;

Narkiewicz, K. ;

Somers, V. K. ;

Januszewicz, A. .

JOURNAL OF HUMAN HYPERTENSION, 2013, 27 (11) :678-685

[23]

Goyal A., 2023, STATPEARLS

[24] Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): a risk score to identify those at high-risk [J].

Gupta, Ajay K. ;

Nasothimiou, Efthimia G. ;

Chang, Choon L. ;

Sever, Peter S. ;

Dahlof, Bjorn ;

Poulter, Neil R. .

JOURNAL OF HYPERTENSION, 2011, 29 (10) :2004-2013

[25] Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial [J].

Hoppe, Uta C. ;

Brandt, Mathias-Christoph ;

Wachter, Rolf ;

Beige, Joachim ;

Rump, Lars Christian ;

Kroon, Abraham A. ;

Cates, Adam W. ;

Lovett, Eric G. ;

Haller, Hermann .

JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION, 2012, 6 (04) :270-276

[26]

Iqbal A.M., 2023, StatPearls

[27] Which cuff should I use? Indirect blood pressure measurement for the diagnosis of hypertension in patients with obesity: a diagnostic accuracy review [J].

Irving, Greg ;

Holden, John ;

Stevens, Richard ;

McManus, Richard J. .

BMJ OPEN, 2016, 6 (11)

[28] Arterial Hypertension Diagnosis and Treatment [J].

Jordan, Jens ;

Kurschat, Christine ;

Reuter, Hannes .

DEUTSCHES ARZTEBLATT INTERNATIONAL, 2018, 115 (33-34) :557-+

[29] Apparent and true resistant hypertension: definition, prevalence and outcomes [J].

Judd, E. ;

Calhoun, D. A. .

JOURNAL OF HUMAN HYPERTENSION, 2014, 28 (08) :463-468

[30] Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial [J].

Kandzari, David E. ;

Boehm, Michael ;

Mahfoud, Felix ;

Townsend, Raymond R. ;

Weber, Michael A. ;

Pocock, Stuart ;

Tsioufis, Konstantinos ;

Tousoulis, Dimitrios ;

Choi, James W. ;

East, Cara ;

Brar, Sandeep ;

Cohen, Sidney A. ;

Fahy, Martin ;

Pilcher, Garrett ;

Kario, Kazuomi .

LANCET, 2018, 391 (10137) :2346-2355

← 1 2 3 4 5 6 7 →